Zobrazeno 1 - 10
of 716
pro vyhledávání: '"John G, Gribben"'
Autor:
Arran Dokal, Weronika E. Borek, Luis Nobre, Salvatore Federico Pedicona, Bela Wrench, Paolo Gallipoli, Andrea Arruda, Amy E. Campbell, Nazrath Nawaz, Harriet R. Ferguson, David N. Perkins, Pedro Moreno-Cardoso, Andrew Thompson, Andrew J.K. Williamson, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas
Publikováno v:
HemaSphere, Vol 7, p e3920765 (2023)
Externí odkaz:
https://doaj.org/article/9587d3fdbfdb464ab33fdd2f65eb362d
Autor:
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e919 (2023)
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the
Externí odkaz:
https://doaj.org/article/54ee041689654f5486a8b741a193c36c
Autor:
Kai Rejeski, Raffaella Greco, Francesco Onida, Isabel Sánchez-Ortega, Chiara Bonini, Anna Sureda, John G. Gribben, Ibrahim Yakoub-Agha, Marion Subklewe
Publikováno v:
HemaSphere, Vol 7, Iss 5, p e889 (2023)
Hematological toxicity represents the most common grade ≥3 toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely understood and its grading and management remains ill-defined. To info
Externí odkaz:
https://doaj.org/article/227c6b423e7b4927bf4310bcb2ec78ef
Autor:
Tarec Christoffer El-Galaly, Verena I. Gaidzik, Mihnea-Alexandru Gaman, Darko Antic, Jessica Okosun, Mhairi Copland, Veronika Sexl, Adele K. Fielding, Robin Doeswijk, Helen Parker, Martin Dreyling, Konstanze Döhner, António Medina Almeida, Elizabeth Macintyre, John G. Gribben, Kirsten Grønbæk, on behalf of the EHA Diversity, Equity, and Inclusion Taskforce
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e842 (2023)
Externí odkaz:
https://doaj.org/article/061eec178a40471bb4aebc1c6c453233
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Follicular lymphoma (FL) is an indolent disease, characterized by a median life expectancy of 18-20 years and by intermittent periods of relapse and remission. FL frequently transforms into the more aggressive diffuse large B cell lymphoma (t-FL). In
Externí odkaz:
https://doaj.org/article/52ee7aea56d745dca2cd50e74bcfe318
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Classical Hodgkin lymphoma (CHL) is unusually sensitive to PD1 inhibition and PDL1 is highly expressed on CHL cells and in the tumor microenvironment. This could be interpreted as evidence of exhaustion, but paradoxically, PD1+ lymphocyte infiltratio
Externí odkaz:
https://doaj.org/article/053d5a6c2df048349881810681491b5d
Autor:
Katarina Kluckova, Andrew J. Clear, Annalisa D’Avola, Laura Z. Rassenti, Thomas J. Kipps, John G. Gribben, John C. Riches
Publikováno v:
HemaSphere, Vol 6, Iss 6, p e722 (2022)
It has been unclear what role metabolism is playing in the pathophysiology of chronic lymphocytic leukemia (CLL). One reason is that the study of CLL metabolism is challenging due to the resting nature of circulating CLL cells. Also, it is not clear
Externí odkaz:
https://doaj.org/article/f8ebec7a7ae54bc1a1256e29c145678a
Autor:
Annalisa D’Avola, Nathalie Legrave, Mylène Tajan, Probir Chakravarty, Ryan L. Shearer, Hamish W. King, Katarina Kluckova, Eric C. Cheung, Andrew J. Clear, Arief S. Gunawan, Lingling Zhang, Louisa K. James, James I. MacRae, John G. Gribben, Dinis P. Calado, Karen H. Vousden, John C. Riches
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 9 (2022)
The synthesis of serine from glucose is a key metabolic pathway supporting cellular proliferation in healthy and malignant cells. Despite this, the role that this aspect of metabolism plays in germinal center biology and pathology is not known. Here,
Externí odkaz:
https://doaj.org/article/f77224ae7f904f2ab572db0a1463b41e
Autor:
Francesca R. Delvecchio, Rachel E.A. Fincham, Sarah Spear, Andrew Clear, Marina Roy-Luzarraga, Frances R. Balkwill, John G. Gribben, Michele Bombardieri, Kairbaan Hodivala-Dilke, Melania Capasso, Hemant M. Kocher
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 5, Pp 1543-1565 (2021)
Background and aims: The presence of tertiary lymphoid structures (TLSs) may confer survival benefit to patients with pancreatic ductal adenocarcinoma (PDAC), in an otherwise immunologically inert malignancy. Yet, the precise role in PDAC has not bee
Externí odkaz:
https://doaj.org/article/b635dee8c698441ab3175efcb13b1c08
Autor:
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn
Publikováno v:
Haematologica, Vol 107, Iss 9 (2022)
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Eligible p
Externí odkaz:
https://doaj.org/article/de39c8b0aa684d82a347ea24d5b709ac